Молекулярные и генетические механизмы атеросклероза и ишемической болезни сердца

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Были изучены распределения генотипов и встречаемости аллелей кандидатных для ишемической болезни сердца генов у мужчин, перенесших инфаркт миокарда в возрасте до 45 лет. Обследовано 279 мужчин, перенесших инфаркт миокарда в возрасте до 45 лет, и 203 здоровых мужчины, составивших группу контроля. Исследованы следующие полиморфизмы: -455 G/А в гене фибриногена, 4G/5G в по­зиции -675 гена ингибитора активатора плазминогена 1 типа, А1166С гена рецептора 1 типа ангиотен­зина II, G-6A гена ангиотензиногена, Sst I гена аполипопротеина CIII, l/D-полиморфизм гена ангиотен- зинпревращающего фермента, рестрикционный полиморфизм гена аполипопротеина Е.

Установлено, что из всех исследованных полиморфизмов генов только носительство Р1А2-аллеля гликопротеина llb/llla рецепторов тромбоцитов является фактором риска развития инфаркта миокар­да у мужчин молодого возраста, а носительство Р1А2/А2-генотипа - фактором риска внезапной смер­ти от коронарных тромбозов.

Об авторах

О. A. Беркович

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Автор, ответственный за переписку.
Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Е. А. Баженова

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Е. В. Волкова

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Н. В. Хромова

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

О. Д. Беляева

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

О. И. Игнатьева

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

В. И. Ларионова

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Е. В. Шляхто

Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова

Email: shabanov@mail.rcom.ru
Россия, Санкт-Петербург

Список литературы

  1. Бурцев В.И, Коннова В А. Дифферинциальная профилактика повторного инфаркта миокарда //Клин. мед. 1999. № 8. С. 16.
  2. Зяблов Ю.И., Округин С.Д., Орлова С.Д. Острые коронарные катастрофы у лиц до 40 лет: результаты 10-летнего (1988-1997) наблюдения в Томске по программе ВОЗ «Регистр острого инфаркта миокарда» // Кардиология. 1999. № 11. С. 47-50.
  3. Константинов В.В., Жуковский В.С., Тимофеева Т.Н. и др. Динамика ишемической болезни сердца и факторов риска среди мужского населения Москвы за период с 1985 по 1995 г. // Тер. архив. 1997. № 1. С. 12-14.
  4. Кузнецова Т, Staessen J.A., WangJ.G. и др. Полиморфизм (типа вставка/отсутствие вставки) гена ангиотензинпревращающего фермента и риск сердечно-сосудистых и почечных заболеваний // Кардиология. 1998. № 7. С. 61-75.
  5. Agerholm-Larsen В., Nordestgaard B.G., Tybjerg-Hansen А. АСЕ gene polymorphism in cardio-vascular disease. Meta-analyses of small and large studies in whites // Arterioscler. Thromb. Vase. Biol. 2000. Vol. 20. P. 484-492.
  6. Alvarez R., Reguero J.R., Batalla A. et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease // Cardiovasc. Res. 1998. Vol. 40 (2). P. 375-379.
  7. Anderson J.L., Muhlestein J.B., Habashi J. et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction // J. Am. Coll. Cardiol. 1999. Vol. 34 (6). P. 1778-1783.
  8. Anderson J.L., Muhlestein J.B., Habashi J. et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction // J. Am. Coll. Cardiol. 1999. Vol. 34 (6). P. 1778-1783.
  9. Ardissino D., Mannucci PM., Merlini P.A. et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction // Blood. 1999. Vol. 94(1). P. 46-51.
  10. Bonnardeaux A., Davies E., Jeunemaitre X., Fe- ry I., Charru A., Glauser E. et al. Angiotensin II type I receptor gene polymorphisms in human essential hypertension // Hypertension. 1994. Vol. 24. P. 63-69.
  11. Brown N.J., Gainer J.V., Nadeau J.H., Vaughan DE. Plasminogen activator inhibitor antigen is increased in hypertensive African Americans with the ACE D allele // Circulation. 1995. Vol. 92 (suppl.). P. 1-552.
  12. Cambien E, Poirier O., Lecerf L. et al. Deletion polymorphism in the gene for angiotensine converting enzyme is a potent risk factor for myocardial infarction // Nature. 1992. Vol. 359. P. 641-644.
  13. Choudhury L., Marsh J. Myocardial infarction in young patients // Am. J. Med. 1999. Vol. 107. P. 254-261.
  14. Dawson S.J., Wiman B., Hamsten A. et al. The two-allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 gene respond differently to interleukin-1 in HepG2 cells // J. Biol. Chem. 1993. Vol. 268. P. 10739-10745.
  15. Doggen C.J.M., Bertina R.M., Cats V.M., Rosendaal F.R. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction // British J. Haematology. 2000. Vol. 110. P. 935-938.
  16. Eriksson P, Kallin B., van’t Hooft F.M., В avenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. P. 1851-1855.
  17. Farmer J.A., Gotto A.M. Dyslipidemia and other risk factor for coronary artery disease / E. Braunwald, ed. // Heart Disease: A Text-book of Cardiovascular Medicine. Philadelphia: Saunders, 1997. P. 1126-1160.
  18. Fatini C., Abbate R., Pepe G. et al. Searching for a better assessment of the individual coronary risk profile: the role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms // Eur. Heart J. 2000. Vol. 21. P. 633-63 8.
  19. Fernandez-Arcas N., Dieguez-Lucena J.L., Munoz-Moran E. et al. The genotype interactions of methylentetrahydrofolate reductase and reninangiotensin system genes are associated with myocardial infarction // Atherosclerosis. 1999. Vol. 145. P. 293-3 00.
  20. Ferns G.A.A., Stocks J., Ritchie C., Galton D.J. Genetic polymorphism of apolipoprotein C-III and insulin in survivors of myocardial infarction // Lancet. 1985. Vol. 2(8450). P. 300-303.
  21. Fournier J.A., Sanchez A., Quero J., Femandez-Cortacero J.A., Gonzalez-Barrero A. Myocardial infarction in men aged 40 years or less; a prospective clinical-angiographic study // Clin. Cardiology. 1996. Vol. 19. P. 631-63 6.
  22. Gardemann A., Humme J., Stricker J. et al. Association of the platelet glycoprotein Illa Р1А1/А2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients // Thromb. Haemost. 1998. Vol. 80 (2). P. 214-217.
  23. Gardemann A., Schwartz O., Haberbosch W. et al. Positive association of the в fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction // Thrombosis and Haemostasis. 1997. Vol. 77. P. 1120-1126.
  24. Gerdes L.U., Gerdes C., Kervinen K. et al. The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction // Circulation. 2000. Vol. 101 (12). P. 1366-1380.
  25. Hagberg J.M., Wilund K.R., Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels // Physiol. Genomics. 2000. Vol. 4. P. 101-108.
  26. Havel R.J., Chao Y.S., Windier EE., Kotite L., Guo L.S.S. Isoprotein specificity in the hepatic uptake of apolipiprotein E and the pathogenesis of familial dysbetalipoproteinemia // Proc. Natl. Acad. Sci. USA. 1980. Vol. 77. P. 4349-4355.
  27. Hayden M.R., Kirk H, Campbell C. et al. DNA polymorphism in and around the Apo-Al-CIII genes and genetic hyperlipidemias // Am. J. Hum. Genet. 1987. Vol. 40. P. 421-430.
  28. Herron K.L., Lofgren IE., Adiconis X., Ordovas J.M., Fernandez ME. Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a healthy population are independent of dietary cholesterol intake // Atherosclerosis. 2006. Vol. 184 (1). P. 113-120.
  29. Hixon JE., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and clevage with Hhal // J. Lipid. Res. 1990. Vol. 31. P. 545-548.
  30. Humphries S.E., Talmud P.J., Hawe E., Bolla M., Day IN., Miller G.J. Apolipoprotein E and coronary heart disease in middle-aged men who smoke: a prospective study // Lancet. 2001. Vol. 3 5 8 (9276). P. 115-119.
  31. Jalowiec D.A., Hill J.A. Myocardial infarction in the young and in women // Cardiovasc. Clin. 1989. Vol. 20. P. 197-206.
  32. Jeunemaitre X, Inoue I., Williams C. et al. Haplotypes of angiotensinogen in essential hypertension // Am. J. Hum. Genet. 1997. Vol. 60 (6). p. 1448-1460.
  33. Jong M.C., Hofker M.H., Havekes L.M. Role of apo Cs in lipoprotein metabolism. Functional differences between Apo Cl, Apo C2, and Apo C3 //Arterioscler. Thromb. Vase. Biol. 1999. Vol. 19. P. 472-484.
  34. Kastrati A., Koch W. K, Gavaz M. et al. PIA polymorphism of glycoprotein Illa and risk of adverse events after coronary stent placement // J. Am. Coll. Cardiol. 2000. Vol. 3 6 (1). P. 84-89.
  35. Keavney B., McKenzie C., Parish S., Palmer A., Clark S., Youngman L. et al. International Studies of Infarct Survival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/ deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls // Lancet. 2000. Vol. 355. P. 434-442.
  36. Kее F, Amouyel P, Fumeron F. et al. Lack of association between genetic variation of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study //Atherosclerosis. 1999. Vol. 145 (1). P. 187-195.
  37. Kessler C., Spitzer C., Stauske D. et al. The apolipoprotein E and b-fibrinogen G/A -455 gene polymorphisms are associated with ischaemic stroke involving large-vessel disease // Arterioscler. Thromb. Vase. Biol. 1997. Vol. 17. P. 2880-2884.
  38. Kharrazi H., Vaisi Raygani A., Sabokroh A.R., Pourmotabbed T. Association between apolipoprotein E polymorphism and coronary artery dis¬ease in the Kermanshah population in Iran // Clin. Biochem. 2006. Vol. 39 (6). P. 613-616.
  39. Lahiri D.K., Bye S., Nurberger J.J.Jr. et al. // J. Biol. Chern, and Biophys. Methods. 1992. Vol. 25. P. 193-205.
  40. Mannucci P.M., Mari D., Merati G. et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolisis proteins. A study in centenarians // Arterioscler. Thromb. Vase. Biol. 1997. Vol. 17 (4). P. 755-759.
  41. Mansfield M.W., Stiskland M.H., Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with noninsulin-dependent diabetes mellitus // Thromb. Haemost. 1995. Vol. 74. P. 842-847.
  42. Margaglione M., Cappucci G., Colaizzo D. et al. The PAI-1 gene locus 4G/5G polymorphism is associated with family history of coronary artery disease // Arterioscler. Thromb. Vase. Biol. 1998. Vol. 18. P. 152-156.
  43. Margaglione M., Cappucci G., Colaizzo D. et al. Fibrinogen plasma levels in apparently healthy general population - relation to environmental and genetic determinants // Thromb. Haemost. 1998. Vol. 80 (5). P. 805-810.
  44. Mikkelsson J., Perola M., Laippala P et al. Glycoprotein Illa PIA polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly // Arterioscler. Thromb. Vase. Biol. 1999. Vol. 19. P. 2573-2578.
  45. Mikkelsson J., Perola M., Penttila A., Goldschmidt-Clermont PJ., Karhunen PJ. The GPIIIa (beta3 integrin) PIA polymorphism in early development of coronary atherosclerosis И Atherosclerosis. 2001. Vol. 154 (3). P. 721-727.
  46. Mikkelsson J., Perola M., Wartiovaara U. et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged finnish men who died suddenly // Thromb. Haemost. 2000. Vol. 84 (1). P. 78-82.
  47. Nakai K., Fusazaki T, Zhang T. et al. Polymorphism of the apolipoprotein E and ACE gene in Japanese patients with myocardial infarction // Coron. Artery Disease. 1998. Vol. 9 (6). P. 329-334.
  48. Nakauchi Y, Suehiro T, Yamamoto M. et al. Sig¬nificance of angiotensin 1-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease //Atherosclerosis. 1996. Vol. 125. P. 161-169.
  49. Newman PJ., Derbes R.S., Aster R.H. The human platelet alloantigens PIA1 and PIA2 are associated with a leucine 33/proline33amino acid polymorphism in membrane glycoprotein Illa, and are distinguishable by DNA typing // J. Clin. Invest. 1989. Vol. 83 (5). P. 1778-1781.
  50. Nishiuma S., Kario K., Kayaba K. et al. Effect of the angiotensinogen gene Met235-Thr variant on blood pressure and other cardiovascular risk factors in two Japanese population // J. Hypertens. 1995. Vol. 13 (7). P. 717-722.
  51. Ossei-Gerning N, Mansfield M.W., Stickland M.H., Wilson I.J., Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography // Arterioscler. Thromb. Vase. Biol. 1997. Vol. 17. P. 33-37.
  52. Rice G.I., Foy C.A., Grant PJ. Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease // Cardiovasc. Research. 1999. Vol. 41. P. 746-753.
  53. Ridker PM., Hennekens C.H., Lindpaintner K. et al. Arterial and venous thrombosis is not associated with 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of U.S. men // Circulation. 1997. Vol. 95. P. 59-62.
  54. Ridker P.M., Hennekens C.H., Schmitz C., Stampfer M.J., Lindpaintner К. PIA1/A2 polymorphism of platelet glycoprotein Illa and risk of myocardial infarction, stroke, and venous thrombosis // Lancet. 1997. Vol. 349. P. 385-388.
  55. Rigat B., Hubert C., Corvol P, Soubrier F PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene//Nucleic. Acid. Res. 1992. Vol. 20. P. 143 3.
  56. Rodriguez-Perez J.C., Rodriguez-Esparragon E, Hernandez-Perera O. et al. PROCAGENE Study Investigators. Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene // J. Am. Coll. Cardiol. 2001. Vol. 37 (6). P. 1536-1542.
  57. Scarabin P.Y, Aillaud M.E, Amouyel P. et al. Associations of fibrinogen, factor VII, and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction // Thromb. Haemost. 1998. Vol. 80 (5). P. 749-756.
  58. Scarabin P.Y, Bara L., Ricard S. et al. Genetic variation at the b-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study / Arteriosclerosis and thrombosis. 1993. Vol. 13. P. 886-891.
  59. Senti M., Aubo C., Bosch M. et al. Platelet glycoprotein Ilb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. The REGICOR Investigators // Clin. Biochem. 1998. Vol. 31 (8). P. 647-651.
  60. Sheu W.H.H., Lee W.J, Jeng C.Y et al. Angiotensinogen gene polymorphism is associated with insulin resistance in nondiabetic men with or without coronary heart disease // Am. Heart. J. 1998. Vol. 136(1). P. 125-131.
  61. Shoulders C.C., Harry P.J, Lagrost L. et al. Variation at the apo AI/CIII/AIV gene complex is associated with eleveted plasma levels of Apo CIII//Atherosclerosis. 1991. Vol. 8 7. P. 239-247.
  62. Sykes T.C.F., Fegan C, Mosquera D. Thrombophilia, polymorphisms, and vascular disease // J. Clin. Pathol. Mol. Pathol. 2000. Vol. 53. P. 300-306.
  63. Talmud P.J., Humphries S.E. Apolipoprotein C- III gene variation and dyslipidaemia // Curr. Opin. Lipidol. 1997. Vol. 8 (3). P. 154-158.
  64. Thogersen A.M., Jansson J.H., Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a fist acute myocardial infarction in both men and women // Circulation. 1998. Vol. 98. P. 2241-2247.
  65. Ту bjarg-Hans en A., Agerholm-Larsen B., Humphries S.E., Abildgaard S., Schnohr P. A common mutation (G-455—A) in the P-fibrinogen promoter is an independent predictor of plas¬ma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on The Copenhagen City Heart Study // J. Clin. Invest. 1997. Vol. 99. P. 3034-3039.
  66. Van der Вот J.G., de Maat M.P, Bots M.L., Haverkate E et al. Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? // Arterioscler. Thromb. Vase. Biol. 1998. Vol. 18 (4). P. 621-625.
  67. Vblcik K.A., Barkley R.A., Hutchinson R.G. et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants // Am. J. Epidemiol. 2006. Vol. 15. № 164 (4). P. 342-348.
  68. Waterworth D.M., Ribalta J., Nicaud V., Dallongeville J., Humphries S.E., Talmud P. Apo CIII gene variants modulate postprandial responce to both glucosae and fat tolerance tests // Circulation. 1999. Vol. 99. P. 1872-1877.
  69. Weiss E.J., Bray PE, Tayback M. et al. A polymorphism of platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis // New Engl. J. Med. 1996. Vol. 334 (17). P. 1090-1094.
  70. Wiwanitkit V. PLA1/A2 polymorphism of the platelet glycoprotein receptor Ilb/IIIa and its correlation with myocardial infarction: an appraisal // Clin. Appl. Thromb. Hemost. 2006. Vol. 12 (1). P. 93-95.
  71. Wu A.H., Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases // Am. J. Cardiol. 2001. Vol. 87 (12). P. 1361-1366.
  72. Zannis V.L, Kardassis D., Zanni E.E. Genetic mutations affecting human lipoproteins, their receptors and their enzymes // Advances in Hum. Genet. 1993. Vol. 21. P. 145-319.
  73. Zee R.Y., Cook N.R., Cheng S., Erlich HA., Lindpaintner K., Ridker PM. Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis // J. Thromb. Haemost. 2006. Vol. 4 (2). P. 341-348.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Беркович О.A., Баженова Е.А., Волкова Е.В., Хромова Н.В., Беляева О.Д., Игнатьева О.И., Ларионова В.И., Шляхто Е.В., 2007


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.